AbbVie 2025 revenue rises 8.6% to $61.16 billion, but full-year EPS dips 1.3%
AbbVie reported fourth-quarter and full-year 2025 results on February 4, 2026. Revenue grew in both periods, and fourth-quarter GAAP diluted EPS was $1.02 versus a loss of $0.02 a year earlier, while full-year GAAP and adjusted EPS each fell slightly. The company also issued 2026 adjusted diluted EPS guidance of $14.37 to $14.57, which excludes acquired IPR&D and milestones expense.
Key points
- Full-year 2025 net revenues were $61.160 billion, up 8.6% on a reported basis; full-year GAAP diluted EPS was $2.36, down 1.3%, and adjusted diluted EPS was $10.00, down 1.2%.
- Fourth-quarter 2025 net revenues were $16.618 billion, up 10.0%; GAAP diluted EPS was $1.02 versus a $0.02 loss a year earlier, and adjusted diluted EPS was $2.71 versus $2.16.
- Full-year 2025 results include an unfavorable impact of $2.76 per share from acquired IPR&D and milestones expense.
- 2026 adjusted diluted EPS guidance is $14.37 to $14.57.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.